The higher prevalence of age-related thyroid diseases, such as HT or longer exposure to endocrine disrupters and thyroid toxic agents, may affect the prevalence of BRAF mutations in elderly subjects as well as the sensitivity of BRAFV600E as a tumor marker. Here, BRAF is linked to neoplasm.